Bio-Techne Corp
TECH65.850USD
+2.360+3.72%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
10.26BMarket Cap
131.57P/E TTM
More Details of Bio-Techne Corp Company
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Bio-Techne Corp Info
Ticker SymbolTECH
Company nameBio-Techne Corp
IPO dateFeb 09, 1989
CEOMr. Kim Kelderman
Number of employees3100
Security typeOrdinary Share
Fiscal year-endFeb 09
Address614 Mckinley Pl N E
CityMINNEAPOLIS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code55413
Phone16123792956
Websitehttps://www.bio-techne.com/
Ticker SymbolTECH
IPO dateFeb 09, 1989
CEOMr. Kim Kelderman
Company Executives of Bio-Techne Corp
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Spatial Biology
President - Diagnostics and Spatial Biology
4.74K
+169.49%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+76.56%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
By RegionUSD
Name
Revenue
Proportion
United States
683.23M
56.02%
EMEA, excluding U.K
266.31M
21.83%
Greater China
100.46M
8.24%
APAC, excluding Greater China
77.26M
6.33%
United Kingdom
54.83M
4.50%
Rest of World
37.55M
3.08%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Other
72.73%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Other
72.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.86%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.05%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.33%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
18.40M
11.82%
-60.83K
-0.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.65%
-512.26K
-5.50%
Jun 30, 2025
State Street Investment Management (US)
5.86M
3.76%
-671.30K
-10.28%
Jun 30, 2025
Atlanta Capital Management Company, L.L.C.
4.29M
2.76%
+573.23K
+15.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.06M
2.61%
-30.89K
-0.75%
Jun 30, 2025
Invesco Capital Management LLC
3.24M
2.08%
+274.96K
+9.28%
Jun 30, 2025
Neuberger Berman, LLC
2.50M
1.61%
-526.06K
-17.38%
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.62M
5.53%
-2.53M
-22.68%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.95%
Invesco Biotechnology & Genome ETF
2.62%
Invesco S&P 500 Equal Weight Health Care ETF
1.79%
VanEck Biotech ETF
1.63%
Neuberger Berman Small-Mid Cap ETF
1.58%
Hilton Small-MidCap Opportunity ETF
1.55%
Thrivent Small-Mid Cap ESG ETF
1.44%
American Century Mid Cap Growth Impact ETF
1.39%
WisdomTree BioRevolution Fund
1.22%
iShares Health Innovation Active ETF
1.2%
View more
Global X Genomics & Biotechnology ETF
Proportion3.95%
Invesco Biotechnology & Genome ETF
Proportion2.62%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.79%
VanEck Biotech ETF
Proportion1.63%
Neuberger Berman Small-Mid Cap ETF
Proportion1.58%
Hilton Small-MidCap Opportunity ETF
Proportion1.55%
Thrivent Small-Mid Cap ESG ETF
Proportion1.44%
American Century Mid Cap Growth Impact ETF
Proportion1.39%
WisdomTree BioRevolution Fund
Proportion1.22%
iShares Health Innovation Active ETF
Proportion1.2%
Dividend
A total of
250.90M
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
View more
Stock Split
Date
Type
Ratio
Nov 01, 2022
Split
1→4
Date
Type
Ratio
Nov 01, 2022
Split
1→4
FAQs
Who are the top five shareholders of Bio-Techne Corp?
The top five shareholders of Bio-Techne Corp are:
The Vanguard Group, Inc. holds 18.40M shares, accounting for 11.82% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.79M shares, accounting for 5.65% of the total shares.
State Street Investment Management (US) holds 5.86M shares, accounting for 3.76% of the total shares.
Atlanta Capital Management Company, L.L.C. holds 4.29M shares, accounting for 2.76% of the total shares.
Geode Capital Management, L.L.C. holds 4.06M shares, accounting for 2.61% of the total shares.
The Vanguard Group, Inc. holds 18.40M shares, accounting for 11.82% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.79M shares, accounting for 5.65% of the total shares.
State Street Investment Management (US) holds 5.86M shares, accounting for 3.76% of the total shares.
Atlanta Capital Management Company, L.L.C. holds 4.29M shares, accounting for 2.76% of the total shares.
Geode Capital Management, L.L.C. holds 4.06M shares, accounting for 2.61% of the total shares.
What are the top three shareholder types of Bio-Techne Corp?
The top three shareholder types of Bio-Techne Corp are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Bio-Techne Corp (TECH)?
As of 2025Q3, 1198 institutions hold shares of Bio-Techne Corp, with a combined market value of approximately 161.18M, accounting for 103.53% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.88%.
What is the biggest source of revenue for Bio-Techne Corp?
In FY2025, the Consumables business generated the highest revenue for Bio-Techne Corp, amounting to 972.29M and accounting for 79.72% of total revenue.
